Key result
Elevated chemerin expression and activation serve as strong markers for CAD development and maintenance.
Why the study?
Chemerin is recognized as a strong marker with increased serum levels in CAD, but its chimeric characteristics and full role in cardiovascular disease are not fully investigated.
Chemerin is a novel adipokine associated with inflammation and adipogenesis that may serve as a strong marker for coronary artery disease.
May inform CAD risk models; leaves open causality and therapeutic targeting in prospective studies.
Currently, coronary artery disease (CAD) is considered a major ailment in humans with widespread prevalence. CAD also accounts for high mortality rates around the world that involves several known risk factors. Chemerin is a novel adipokinine that is associated with inflammation and adipogenesis. Furthermore, experimental and clinical data indicate that localized as well as circulating chemerin expression and activation are elevated in numerous metabolic and inflammatory diseases including psoriasis, obesity, type 2 diabetes, metabolic syndrome and cardiovascular disease. Chemerin is accepted as being a strong marker because the serum chemerin levels are increased in a CAD condition. However, the chimeric characteristics of chemerin have not been fully investigated. Although chemerin is known to be responsible for CAD development among other factors, authors still investigate it at the marker level. This review focuses on chemerin expression, processing, biological function and relevance to human diseases, and on the role of chemerin in the maintenance of a cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
İnci et al. (2016) conducted a review in Coronary artery disease and cardiovascular disease. Chemerin was evaluated. Chemerin expression and activation are elevated in cardiovascular disease, serving as a strong marker for coronary artery disease development and maintenance.